Clinical Trials

List clinical trials by disease

The results of your search are listed below. To view the details of a trial or study, click on the "see details >" link. Or start a new search.

Searched for: Acute Myeloid Leukemia (AML). 36 results shown below.

Fludarabine Phosphate and Total Body Irradiation Followed by a Donor Peripheral Stem Cell Transplant in Treating Patients With Myelodysplastic Syndromes or Myeloproliferative Disorders

[Complete title: Low-dose TBI Dose Escalation to Decrease Risks of Progression and Graft Rejection after Hematopoietic Cell Transplantation with Nonmyeloablative Conditioning as Treatment for Untreated Myelodysplastic Syndrome or Myeloproliferative Disorders -- A Multi-Center Trial]
Principal Investigator: Brenda Sandmaier, MD
Study Number: 2056.00
Phase: II

Selective Depletion of CD45RA+T Cells From Allogeneic Peripheral Blood Stem Cell Grafts for the Prevention of GVHD

[Complete title: A Multi-center Phase II Study of Selective Depletion of CD45RA+ T cells from Allogeneic Peripheral Blood Stem Cell Grafts for the Prevention of GVHD]
Principal Investigator: Marie Bleakley, MD
Study Number: 2222.00
Phase: II

Feasibility and Outcomes of Allogeneic HCT Compared to Chemotherapy in Older AML Patients

[Complete title: Feasibility and Outcomes of Allogeneic Hematopoietic Cell Transplantation (HCT) Compared to Conventional Therapy for Older and Medically Infirm Patients Diagnosed with Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes: A Prospective Observational Study]
Principal Investigator: Mohamed Sorror, MD, MSc
Study Number: 2368.00
Phase: NA

Clofarabine and Low-Dose Total-Body Irradiation in Treating Patients With Acute Myeloid Leukemia Undergoing Donor Peripheral Blood Stem Cell Transplant

[Complete title: A Phase II Study of Optimally Dosed Clofarabine in Combination with Low-Dose TBI to Decrease Relapse Rates after Related or Unrelated Donor Hematopoietic Cell Transplantation in Patients with AML]
Principal Investigator: Brenda Sandmaier, MD
Study Number: 2430.00
Phase: II

Yttrium Y 90 Anti-CD45 Monoclonal Antibody BC8 Followed by Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic Syndrome

[Complete title: A Study Evaluating Escalating Doses of 90Y-DOTA-BC8 (anti-CD45) Antibody followed by Allogeneic Stem Cell Transplantation for High-Risk Acute Myeloid Leukemia (AML) Acute Lymphoblastic Leukemia (ALL), or Myelodysplastic Syndrome (MDS)]
Principal Investigator: Brenda Sandmaier, MD
Study Number: 2468.00
Phase: I

Selecting a Favorable KIR Donor in Unrelated HCT for AML

[Complete title: KIR Genotyping for Unrelated Donor (URD) Selection Prior to Hematopoietic Cell Transplantation (HCT) for AML: Selecting a Favorable KIR Donor]
Principal Investigator: Ann Woolfrey, MD
Study Number: 2484.00
Phase: NA

Laboratory-Treated T Cells in Treating Patients With High-Risk Relapsed Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia Previously Treated With Donor Stem Cell Transplant

[Complete title: Phase I/II Study of Adoptive Immunotherapy with Virus Specific CD8+ T Cells that have been Transduced to Express a WT1-Specific T Cell Receptor for Patients with High Risk or Relapsed AML, MDS, or CML]
Principal Investigator: Merav Bar, MD
Study Number: 2498.00
Phase: I/II

Treosulfan and Fludarabine Phosphate With or Without Total Body Irradiation Before Donor Stem Cell Transplant in Treating Patients With Myelodysplastic Syndrome

[Complete title: A Randomized Phase II Multi-Center Study of Treosulfan, Fludarabine and Low-Dose TBI as Conditioning for Allogeneic Hematopoietic Cell Transplantation in Patients with Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML)]
Principal Investigator: Joachim Deeg, MD
Study Number: 2524.00
Phase: II

Laboratory-Treated Donor Cord Blood Cell Infusion Following Combination Chemotherapy in Treating Younger Patients With Relapsed or Refractory Acute Myeloid Leukemia

[Complete title: Pilot Study Evaluating the Use of Ex Vivo Expanded Cord Blood Progenitors as Supportive Care Following Chemotherapy (FLAG) in Patients with AML or Acute Leukemia of Ambiguous Lineage]
Principal Investigator: Ann Dahlberg
Study Number: 2584.00
Phase: Pilot

Donor Umbilical Cord Blood Transplant With or Without Ex-Vivo Expanded Cord Blood Progenitor Cells in Treating Patients With Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia, or Myelodysplastic Syndromes

[Complete title: Multi-Center, Open-Label Randomized Study of Single or Double Myeloablative Cord Blood Transplantation with or without Infusion of Off–the-Shelf Ex Vivo Expanded Cryopreserved Cord Blood Progenitor Cells in Patients with Hematologic Malignancies]
Principal Investigator: Colleen Delaney, MD, MSc
Study Number: 2603.00
Phase: II

Liposomal Cytarabine and Daunorubicin (CPX-351) for Adults with Untreated High-Risk MDS and Non-APL AML at High Risk of Treatment-Related Mortality

[Complete title: Liposomal Cytarabine and Daunorubicin (CPX-351) for Adults with Untreated High-Risk MDS and Non-APL AML at High Risk of Treatment-Related Mortality]
Principal Investigator: Roland Walter, MD
Study Number: 2642.00
Phase: Pilot

Decitabine Followed By Mitoxantrone Hydrochloride, Etoposide, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes

[Complete title: Mitoxantrone, Etoposide, and Cytarabine (MEC) Following Epigenetic Priming with Decitabine in Adults with Relapsed/Refractory Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndromes (MDS): A Phase I/II Study]
Principal Investigator: Roland Walter, MD
Study Number: 2652.00
Phase: I/II

Selective Depletion of CD45RA+ T Cells from Allogeneic Peripheral Blood Stem Cell Grafts for the Prevention of GVHD in Children

[Complete title: A Phase II Study of Selective Depletion of CD45RA+ T Cells from Allogeneic Peripheral Blood Stem Cell Grafts for the Prevention of GVHD in Children]
Principal Investigator: Marie Bleakley, MD
Study Number: 2660.00
Phase: II

Abatacept as GVHD Prophylaxis Phase 2

[Complete title: Abatacept Combined with a Calcineurin Inhibitor and Methotrexate for Graft Versus Host Disease Prophylaxis: A Randomized Controlled Trial]
Principal Investigator: Leslie Kean
Study Number: 2692.00
Phase: Pilot

Filgrastim, Cladribine, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With Newly Diagnosed or Relapsed/Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes

[Complete title: A Phase 1/2 Trial of G-CSF, Cladribine, Cytarabine, and Dose-Escalated Mitoxantrone (G-CLAM) in Adults with Newly Diagnosed or Relapsed/Refractory Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndromes (MDS)]
Principal Investigator: Roland Walter, MD
Study Number: 2734.00
Phase: I/II

Outpatient Induction Chemotherapy in Treating Patients With Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome

[Complete title: Feasibility of Outpatient Induction Chemotherapy for Adult Patients with Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome]
Principal Investigator: Pamela Becker, MD, PhD
Study Number: 7910
Phase: Pilot

Treatment for Relapsed/Refractory AML Based on a High Throughput Drug Sensitivity Assay

[Complete title: Treatment for Relapsed/Refractory AML Based on a High Throughput Drug Sensitivity Assay]
Principal Investigator: Pamela Becker, MD, PhD
Study Number: 8003
Phase: Pilot

Decitabine and Cytarabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia, High Risk Myelodysplastic Syndrome, or Myeloproliferative Neoplasm

[Complete title: Decitabine plus Cytarabine for Induction of Remission in Newly Diagnosed Elderly Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)]
Principal Investigator: Pamela Becker, MD, PhD
Study Number: 9019
Phase: II

Pentostatin and Lymphocyte Infusion in Preventing Graft Rejection in Patients Who Have Undergone Donor Stem Cell Transplant

[Complete title: Pentostatin and Donor Lymphocyte Infusion for Low Donor T-Cell Chimerism After Hematopoietic Cell Transplantation - A Multicenter Trial]
Principal Investigator: Brenda Sandmaier, MD
Study Number: 1825.00
Phase: II

Umbilical Cord Blood Transplant, Cyclophosphamide, Fludarabine Phosphate, and Total-Body Irradiation in Treating Patients With Hematologic Disease

[Complete title: Transplantation of Umbilical Cord Blood for Patients with Hematological Diseases with Cyclophosphamide/Fludarabine/Total Body Irradiation Myeloablative Preparative Regimen]
Principal Investigator: Colleen Delaney, MD, MSc
Study Number: 2010.00
Phase: II

Iodine I 131 Monoclonal Antibody BC8, Fludarabine Phosphate, Cyclophosphamide, Total-Body Irradiation and Donor Bone Marrow Transplant in Treating Patients With Advanced Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or High-Risk Myelodysplastic Syndrome

[Complete title: Hematopoietic Bone Marrow Transplantation for Patients with High-Risk Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), or Myelodysplastic Syndrome (MDS) using Related HLA-Mismatched Donors: A Trial Using Radiolabeled Anti-CD45 Antibody Combined with Immunosuppression Before and After Transplantation]
Principal Investigator: Johnnie Orozco, MD, PhD
Study Number: 2186.00
Phase: II

Fludarabine Phosphate, Cyclophosphamide, Total-Body Irradiation, and Donor Bone Marrow Transplant Followed by Donor Natural Killer Cell Therapy, Mycophenolate Mofetil, and Tacrolimus in Treating Patients With Hematologic Cancer

[Complete title: A Phase I/II Study Evaluating the Safety and Efficacy of Adding a Single Prophylactic Donor Lymphocyte Infusion (DLI) of Natural Killer Cells Early After Nonmyeloablative, HLA-Haploidentical Hematopoietic Cell Transplantation]
Principal Investigator: Brenda Sandmaier, MD
Study Number: 2230.00
Phase: I/II

Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer

[Complete title: Transplantation of Umbilical Cord Blood in Patients with Hematological Malignancies Using a Reduced-intensity Preparative Regimen]
Principal Investigator: Rachel Salit
Study Number: 2239.00
Phase: II

Treosulfan, Fludarabine Phosphate, and Total-Body Irradiation in Treating Patients With Hematological Cancer Who Are Undergoing Donor Umbilical Cord Blood Transplant

[Complete title: Transplantation of Umbilical Cord Blood in Patients with Hematological Malignancies Using a Treosulfan Based Preparative Regimen]
Principal Investigator: Colleen Delaney, MD, MSc
Study Number: 2275.00
Phase: II

Computer-Guided Glucose Management Systems in Treating Patients With Hyperglycemia Who Have Undergone Blood and Bone Marrow Transplant

[Complete title: Use of a Computer-Guided Glucose Management System for Patients Undergoing Blood and Marrow Transplants (BMT)]
Principal Investigator: Merav Bar, MD
Study Number: 2425.00
Phase: Pilot

Donor Atorvastatin Treatment for Preventing Severe Acute Graft-Versus-Host Disease in Patients Undergoing Allogeneic Peripheral Blood Stem Cell Transplantation

[Complete title: Donor Statin Treatment for Prevention of Severe Acute GVHD after Myeloablative Hematopoietic Cell Transplantation]
Principal Investigator: Marco Mielcarek, MD
Study Number: 2545.00
Phase: II

Donor Atorvastatin Treatment in Preventing Severe Acute GVHD After Nonmyeloablative Peripheral Blood Stem Cell Transplant in Patients With Hematological Malignancies

[Complete title: Donor Statin Treatment for Prevention of Severe Acute GVHD after Nonmyeloablative Hematopoietic Cell Transplantation]
Principal Investigator: Marco Mielcarek, MD
Study Number: 2546.00
Phase: II

A Phase 1b Study Evaluating AMG 232 Alone and in Combination With Trametinib in Acute Myeloid Leukemia

[Complete title: A Phase 1 Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AMG 232 in Adult Subjects With Relapsed/Refractory Acute Myeloid Leukemia]
Principal Investigator: Pamela Becker, MD, PhD
Study Number: 20132322
Phase: I

A Phase I Study of IGN523 in Subjects With Relapsed or Refractory AML

[Complete title: A Phase 1, Open-Label Study Evaluating the Safety, Pharmacokinetics, and Clinical Activity of IGN523 in Subjects with Relapsed or Refractory Acute Myeloid Leukemia]
Principal Investigator: Pamela Becker, MD, PhD
Study Number: 20140188
Phase: I

Phase I Clinical Study of CWP232291 in Acute Myeloid Leukemia Patients

[Complete title: A Phase I Clinical Study of CWP232291 in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) or Chronic Myelomonocytic Leukemia-2 (CMML-2), Myelodysplasic Syndrome Having Failed Hypomethylating Treatment (MDS) and High-Risk Myelofibrosis (MF)]
Principal Investigator: John Pagel, MD, PhD
Study Number: 2513.00
Phase: I

Low Dose Cytarabine and Lintuzumab-Ac225 in Older Patient

[Complete title: A Phase I/II Study of Low Dose Cytarabine and Lintuzumab-Ac225 in Older Patients with Untreated Acute Myeloid Leukemia]
Principal Investigator: John Pagel, MD, PhD
Study Number: 2572.00
Phase: I/II

A Study of CSL362 in Patients With CD123+ Acute Myeloid Leukemia Currently in Remission

[Complete title: A Phase 1 Study of CSL362 (Anti-IL3Ra / Anti-CD123 Monoclonal Antibody) in Patients with CD123+ Acute Myeloid Leukemia in Complete Remission or Complete Remission with Incomplete Platelet Recovery at High Risk for Early Relapse]
Principal Investigator: Roland Walter, MD
Study Number: 2616.00
Phase: I

ety Study of Gene Modified Donor T-cells Following Partially Mismatched Stem Cell Transplant

[Complete title: A Phase1/2 Dose Escalation Study Evaluating Safety and Feasibility of BPX-501 T Cells after Partially Mismatched, Related, T Cell-Depleted HSCT]
Principal Investigator: Brenda Sandmaier, MD
Study Number: 2653.00
Phase: I

A Safety Study of SGN-CD33A in AML Patients

[Complete title: A Phase 1 Trial of SGN-CD33A in Patients with CD33-Positive Acute Myeloid Leukemia]
Principal Investigator: Roland Walter, MD
Study Number: 2690.00
Phase: I

Safety Study of Oral Azacitidine (CC-486) as Maintenance Therapy After Allogeneic Hematopoietic Stem Cell Transplantation in Subjects With Acute Myeloid Leukemia or Myelodysplastic Syndromes

[Complete title: A Phase 1/2, Dose and Schedule Finding Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Oral Azacitidine (CC-486) in Subjects with Acute Myeloid Leukemia or Myelodysplastic Syndromes after Allogeneic Hematopoietic Stem Cell Transplantation]
Principal Investigator: Bart Scott, MD
Study Number: 2709.00
Phase: I/II

Standard of Care +/- Midostaurin to Prevent Relapse Post Stem Cell Transplant in Patients With FLT3-ITD Mutated AML (RADIUS)

[Complete title: A Phase II, Randomized, Comparative Trial of Standard of Care, with or without Midostaurin to Prevent Relapse following Allogeneic Hematopoietic Stem Cell Transplantation in Patients with FLT3-ITD Mutated Acute Myeloid Leukemia]
Principal Investigator: Bart Scott, MD
Study Number: 9037
Phase: II

Select a disease from the list below:

Limit results to studies enrolling:

OR

Search by Keyword, Investigator Name or Study ID#:

Limit results to studies enrolling:

OR

View all studies

Limit results to studies enrolling:

Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.

Please remember:

  • Talk to your health care providers first before making decisions about your health care.
  • Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each study.

Subscribe to an RSS feed of all trials